Literature DB >> 10860544

Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide.

S R Paik1, H J Shin, J H Lee.   

Abstract

alpha-Synuclein is a component of abnormal protein depositions of Lewy bodies and senile plaques found in Parkinson's and Alzheimer's diseases, respectively. By using chemical coupling reagents such as dicyclohexylcarbodiimide or N-(ethoxycarbonyl)-2-ethoxy-1, 2-dihydroquinoline, the protein was shown to experience self-oligomerization in the presence of either copper(II) or Abeta25-35. The oligomers which appeared as a ladder on a 10-20% Tricine/SDS-PAGE have been suggested to participate in the formation of protein aggregations by possibly providing a nucleation center. Since oxidatively modified protein could increase its own tendency toward protein aggregation, metal-catalyzed oxidation of alpha-synuclein has been examined with copper(II) and hydrogen peroxide in the absence of the coupling reagent. Intriguingly, the protein was also self-oligomerized into an SDS-resistant ladder on the gel. This biochemically specific copper-mediated oxidative oligomerization was shown to be dependent upon the acidic C-terminus of alpha-synuclein because the C-terminally truncated proteins such as alpha-syn114 and alpha-syn97 were not affected by the metal and hydrogen peroxide. More importantly, the oxidative oligomerization was synergistically enhanced by the presence of Abeta25-35, indicating that the peptide interaction with alpha-synuclein facilitated the copper(II) binding to the acidic C-terminus and subsequent oxidative crosslinking. It has been, therefore, suggested that abnormalities in copper and H(2)O(2) homeostasis and certain pathological factors functionally similar to the Abeta25-35 could play critical roles in the metal-catalyzed oxidative oligomerization of alpha-synuclein, which may lead to possible protein aggregation and neurodegenerations. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860544     DOI: 10.1006/abbi.2000.1822

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  34 in total

1.  Membrane insertion exacerbates the α-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all α-synuclein-Cu(II) complexes.

Authors:  Jenifer S Calvo; Neha V Mulpuri; Alex Dao; Nabeeha K Qazi; Gabriele Meloni
Journal:  Free Radic Biol Med       Date:  2020-07-23       Impact factor: 7.376

2.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

Review 3.  Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease.

Authors:  Marco Bisaglia; Isabella Tessari; Stefano Mammi; Luigi Bubacco
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

4.  TiO2 Nanoparticles as Potential Promoting Agents of Fibrillation of α-Synuclein, a Parkinson's Disease-Related Protein.

Authors:  Soheila Mohammadi; Maryam Nikkhah
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

Review 5.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

Review 6.  Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.

Authors:  Erin J McAllum; David I Finkelstein
Journal:  J Mol Neurosci       Date:  2016-08-08       Impact factor: 3.444

7.  Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.

Authors:  Yunden Jinsmaa; Patricia Sullivan; Daniel Gross; Adele Cooney; Yehonatan Sharabi; David S Goldstein
Journal:  Neurosci Lett       Date:  2014-03-23       Impact factor: 3.046

8.  Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein.

Authors:  J R Requena; D Groth; G Legname; E R Stadtman; S B Prusiner; R L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

9.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.